Aptose Biosciences Inc. closes public offering of common shares

On July 20, 2020, Aptose Biosciences Inc. closed its public offering of common shares, amounting to gross proceeds of approximately US$61.6 million. This was a U.S.-only offering and no shares were offered or sold in Canada.

The proceeds from this offering will be used to accelerate and expand clinical trials for Aptose's CG-806 and APTO-253 drugs as well as to acquire and fund additional clinical assets.

McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Souliere and included Isabelle Nazon and Laetitia Ouedraogo.